Advances in systemic therapies for metastatic castration-resistant prostate cancer

被引：3
|
作者：
Pant, Manish K. [1 ]
Abughaban, Ahmed [2 ]
Aragon-Ching, Jeanny B. [1 ]
机构：
[1] George Washington Univ, Div Hematol & Oncol, Dept Med, Med Ctr, Washington, DC 20037 USA
[2] George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA
来源：
FUTURE ONCOLOGY | 2014年 / 10卷 / 14期
关键词：
abiraterone acetate; androgen deprivation therapy; chemotherapy; enzalutamide; immunotherapy; metastatic castration-resistant prostate cancer; radium; zoledronic acid; MITOXANTRONE PLUS PREDNISONE; PHASE-III TRIAL; ANDROGEN-RECEPTOR GENE; SIPULEUCEL-T; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; EMITTING RA-223; BONE METASTASES; DOUBLE-BLIND; OPEN-LABEL;
D O I：
10.2217/fon.14.128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The landscape of treatment for metastatic castration-resistant prostate cancer has rapidly evolved during the last 5 years alone. In this review, standard therapies as well as recent advances in the systemic treatment for prostate cancer are explored. Pivotal trial data are summarized with emphasis on indications for various anti-androgen drugs, androgen-biosynthesis inhibitors, chemotherapy, immunotherapy and bone-targeted agents. The clinical, biochemical and radiographic outcomes for men with metastatic castration-resistant prostate cancer are improving with the establishment of several promising novel agents.
引用
收藏
页码：2213 / 2226
页数：14
相关论文
共 50 条
  • [1] Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer
    Liu, Jane Jijun
    Zhang, Jingsong
    [J]. CANCER CONTROL, 2013, 20 (03) : 181 - 187
  • [2] Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
    Hatano, Koji
    Nonomura, Norio
    [J]. WORLD JOURNAL OF MENS HEALTH, 2023, 41 (04): : 769 - 784
  • [3] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [4] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    [J]. FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403
  • [5] Advancing therapies in metastatic castration-resistant prostate cancer
    Baciarello, Giulia
    Gizzi, Marco
    Fizazi, Karim
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (16) : 1797 - 1804
  • [6] Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer
    Rajpar, Shanna
    Fizazi, Karim
    [J]. CANCER JOURNAL, 2013, 19 (01): : 66 - 70
  • [7] Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
    MacVicar, Gary R.
    Hussain, Maha H.
    [J]. CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 252 - 260
  • [8] Management of Metastatic Castration-Resistant Prostate Cancer Recent Advances
    Mukherji, Deborah
    Eichholz, Andrew
    De Bono, Johann S.
    [J]. DRUGS, 2012, 72 (08) : 1011 - 1028
  • [9] Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
    Nuhn, Philipp
    De Bono, Johann S.
    Fizazi, Karim
    Freedland, Stephen J.
    Grilli, Maurizio
    Kantoff, Philip W.
    Sonpavde, Guru
    Sternberg, Cora N.
    Yegnasubramanian, Srinivasan
    Antonarakis, Emmanuel S.
    [J]. EUROPEAN UROLOGY, 2019, 75 (01) : 88 - 99
  • [10] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    [J]. PATHOLOGE, 2021, 42 (04): : 431 - 438
12345